| Category | Min Lots | Shares | Amount |
|---|---|---|---|
| Retail (sNII) | 1 | 30 | ₹13,800 |
| HNI / NII | 15 | 450 | ₹2,07,000 |
| bHNI / bNII | 73 | 2,190 | ₹10,07,400 |
| Category | Sub (×) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 43,64,510 (50.00%) | — | ₹20,076.75 Cr |
| NII / HNI (Total) | — | 13,09,354 (15.00%) | — | ₹6,023.03 Cr |
| Retail Investors | — | 30,55,159 (35.00%) | — | ₹14,053.73 Cr |
| Total ** | — | 87,29,023 (100.00%) | — | ₹401,535.06 Cr |
| Metric | 31-Mar-21 | 31-Mar-20 | 31-Mar-19 |
|---|---|---|---|
| Revenue | 430.70 | 331.34 | 311.53 |
| PAT | 15.57 | 16.21 | 63.82 |
| EBITDA | — | — | — |
| Net Worth | — | — | — |
| Total Assets | 296.12 | 338.49 | 298.18 |
| Reserves | — | — | — |
| Borrowings | — | — | — |
Incorporated in 2001, Windlas Biotech Ltd is one of the leading companies in the pharmaceutical formulations contract development and manufacturing organizations (CDMO) segment in India. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
It further sells its own branded products in the trade generics and OTC markets. Currently, the focus of the company is to launch complex generic products in the chronic therapeutic category related to lifestyle-related disorders. The business operates in 3 verticals; 1. CDMO Products and services, 2. Domestic trade generics and Over-the-counter (OTC) market (nutraceutical and health supplement products), and 3. Export.
Leading pharma companies i.e. Pfizer Ltd, Sanofi India Ltd, Cadila Healthcare Ltd, Emcure Pharmaceuticals Ltd, Eris Lifesciences Ltd, Intas Pharmaceuticals Ltd, and Systopic Laboratories Private Limited are some of the marquee customers of Windlas Biotech. Its manufacturing facilities are located at Dehradun with an installed operating capacity of 7,063.83 million tablets/ capsules, 54.46 million pouch/ sachet, and 61.08 million liquid bottles.
Competitive strengths